Experiments carried out using agonistic anti-TRAIL-R1 (MAPATUMUMAB) or anti-TRAIL-R2 (LEXATUMUMAB) mAbs provided evidence that the latter one added together with LBW242 induced a high rate of apoptosis of all the four ovarian cancer cell lines here studied (data not shown). Here, TNFRSF10A is linked to ovarian cancer.